Grants Awarded

Thank you for your interest in our research. For your convenience we have listed grants awarded by principle investigator and by title.

Terry A. Day, M.D.

  • Rita M. Young, M.D., PI, Terry A. Day, M.D., Co-Investigator. Targeting mTOR as a Novel Mechanism-Based Therapy for Head and Neck Cancer. NIH/NCI, $99,999, 7/2009 to 6/2011.

Christopher M. Discolo, M.D.

  • Christopher M. Discolo, M.D., PI, David R. White, M.D., Co-Investigator. A Prospective, Multi-Center, Non-Randomized Clinical Trial to Evaluate the Ear Effusion Detection and Characterization System (EEDCS) to Detect and Characterize Middle Ear Fluid in Children. OtoSonics Inc., $23,500, 7/2010 to 6/2011.
  • Christopher M. Discolo, M.D., PI. Non-Randomized, Feasibility Trial to Evaluate the Ear Effusion Detection and Characterization System (EEDCS) to Detect and Characterize Middle Ear Fluid in Children. OtoSonics Inc., $15,000, 4/2010 to 3/2011.

Judy Dubno, Ph.D.

  • Judy R. Dubno, Ph.D., PI. Auditory Analysis and Speech Recognition. NIH/NIDCD, $137,625, 7/17/09 to 6/30/11.
  • Judy R. Dubno, Ph.D., PI. Auditory Analysis and Speech Recognition. NIH/NIDCD, $297,338, 7/1/06 to 6/30/11.
  • Judy R. Dubno, Ph.D., PI. Automated Hearing Tests. Audiology Inc. and NIH/NIDCD, $132,868, 4/1/10 to 3/13/13.
  • Judy R. Dubno, Ph.D., PI. Experimental and Clinical Studies of Presbyacusis. NIH/NIDCD, $348,432, 7/17/09 to 6/30/11.
  • Judy R. Dubno, Ph.D., PI. Experimental and Clinical Studies of Presbyacusis. NIH/NIDCD, $1,843,561, 8/1/08 to 7/31/13.
  • Judy R. Dubno, Ph.D., PI. Multi-site Study of the Efficacy of Speech Perception Training for Hearing-Aid Users. NIH/NIDCD, $300,640, 7/1/10 to 6/30/15.

Mark Eckert, Ph.D.

  • Mark Eckert, Ph.D., PI. Neural Changes Underlying Speech-Perception Training in the Aging Brain. Deafness Research Foundation, $50,000, 9/1/09 to 8/31/10.
  • Kelly C. Harris, M.D.
  • Kelly C. Harris, M.D., PI. Auditory Temporal Processing in the Aging Ear and Brain (Clinical Research). NIH/NIDCD, $52,719, 7/17/09 to 6/30/10.
  • Kelly C. Harris, M.D., PI. Auditory Temporal Processing in the Aging Ear and Brain (Research Training). NIH/NIDCD, $124,127, 9/1/07 to 8/31/12.

Joshua D. Hornig, M.D.

  • Joshua D. Hornig, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. A Prospective, Blinded, Randomized, Controlled Trial Comparing Wound Drainage and Post-Operative Complications with and without the Use of EVICEL Fibrin Sealant in Thyroidectomy. Ethicon, $100,000, 3/2010 to 2/2012.

Paul R. Lambert, M.D.

  • Paul R. Lambert, M.D., PI, Ted A. Meyer, M.D., Co-Investigator. An Open-Label, Long-Term, Treatment Study to Assess the Long-Term, Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus. Icon Clinical Research Inc. and Merz Pharmaceuticals, $131,300, 12/2009 to 12/2011.
  • Paul R. Lambert, M.D., PI, Ted A. Meyer, M.D., Co-Investigator. An Open-Label, Long-Term, Treatment Study to Assess the Long-Term, Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus. Icon Clinical Research Inc. and Merz Pharmaceuticals, $123,500, 8/2010 to 8/2012.
  • Paul R. Lambert, M.D., PI. A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 1B Study of Oto-104 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere's Disease. Otonomy Inc., $106,563, 12/2009 to 12/2010.

Ted A. Meyer, M.D., Ph.D.

  • Ted A. Meyer, M.D., Ph.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. The Effects of Apical Stimulation of the Cochlea Using Fine Structure Processing. Med El Coro, $43,500, 12/2009 to 12/2012.
  • Ted A. Meyer, M.D., Ph.D., PI,, Abby Connell, MEd, Co-Investigator. Electric-Acoustic Systems (EAS) Investigational Plan. MED-EL Corporation, $30,500, 8/2010 to 7/2012.
  • Ted A. Meyer, M.D., Ph.D., PI, Meredith Edgerton, AuD, Co-Investigator. Evaluation of the ClearVoice Strategy in Adults Using HiResolution Fidelity 120 Sound Processing. Advanced Bionics, $9,750, 12/2009 to 12/2011.
  • Ted A. Meyer, M.D., Ph.D., PI, Abby Connell, MEd, Co-Investigator. Market Assessment Evaluation. Cochlear Americas, $3,750, 7/2009 to 7/2011.
  • Paul R. Lambert, M.D., PI, Ted A. Meyer, M.D., Ph.D., Co-Investigator. An Open-Label, Long-Term, Treatment Study to Assess the Long-Term, Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus. Icon Clinical Research Inc. and Merz Pharmaceuticals, $131,300, 12/2009 to 12/2011.
  • Paul R. Lambert, M.D., PI, Ted A. Meyer, M.D., Ph.D., Co-Investigator. An Open-Label, Long-Term, Treatment Study to Assess the Long-Term, Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus. Icon Clinical Research Inc. and Merz Pharmaceuticals, $123,500, 8/2010 to 8/2012.

Shaun A. Nguyen, M.D., CPI

  • Shaun A. Nguyen, M.D., PI. Otology Data Collection Project CHEER. Academy of Otolaryngology – Head and Neck Surgery & Duke University, 1/2010 to 1/2011.
  • Ted A. Meyer, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. The Effects of Apical Stimulation of the Cochlea Using Fine Structure Processing. Med El Coro, $43,500, 12/2009 to 12/2012.
  • Ted A. Meyer, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. Evaluation of the ClearVoice Strategy in Adults Using HiResolution Fidelity 120 Sound Processing. Advanced Bionics, $9,750, 12/2009 to 12/2011.
  • Ted A. Meyer, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. Market Assessment Evaluation. Cochlear Americas, $3,750, 07/2009 to 7/2011.
  • Rodney Schlosser, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. Management of Allergic Rhinitis Patients with Nasal Steroids and Low Pressure Nasal Irrigation with Isotonic Saline: A Prospective Pilot Study. NellMed Pharmaceuticals Inc., $67,380, 12/2009 to 6/2011.
  • David R. White, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. Natural History Study Incidence of Otorrhea Following Tympanostomy Tube Insertion in a Cohort of Children Aged 6 Months to 12 Years. Alcon Inc., $37,750, 7/2010 to 6/2011.
  • Joshua D. Hornig, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. A Prospective, Blinded, Randomized, Controlled Trial Comparing Wound Drainage and Post-Operative Complications with and without the Use of EVICEL Fibrin Sealant in Thyroidectomy. Ethicon, $100,000, 3/2010 to 2/2012.

Rodney Schlosser, M.D.

  • Rodney Schlosser, M.D., Mentor and co-investigator. (PI, Andreoli S). Ciliary dysfunction in children with otitis media and tobacco exposure. MUSC University Research Committee, $2,000, 2010.
  • Rodney Schlosser, M.D., Mentor and co-investigator. (PI, Andreoli S). Ciliary dysfunction in pediatric atopic disease. AAOA, $5,000, 2009 to 10.
  • Rodney Schlosser, M.D., Mentor and co-investigator. (PI, Mulligan JK). Contribution of VD3 deficiency to immune dysfunction in children with chronic rhinosinusitis. American Society of Pediatric Otolaryngology, $20,000, 2010 to 2011.
  • Rodney Schlosser, M.D., Mentor and co-investigator. (PI, Mulligan JK). Effects of fungal antigen exposure on epithelial cell induction of dendritic cell maturation in patients with AFRS. AAOA, $5,000, 2009 to 2010.
  • Rodney Schlosser, M.D., Mentor and co-investigator. (PI, Mulligan JK). Effects of second hand smoke on dendritic cell regulation and function in chronic rhinosinusitis. Flight Attendants Medical Research Institute,Young Clinical Scientist Award, $225,000, 2010 to 2013.
  • Rodney Schlosser, M.D., PI. Determinants of Surgical/Medical Management Outcomes in Chronic Rhinosinusitis. American Rhinological Society & Oregon Health Sciences University, 6/2009 to 6/2012.
  • Rodney Schlosser, M.D., Mentor and co-investigator. (PI, O’ Connell B). Immunolocalization and regulation of Th2 cells in allergic fungal rhinosinusitis. AAOA, $5,000, 2009 to 10.
  • Rodney Schlosser, M.D., PI. Impact of Intraoperative Hydrodebrider Treatment on Post-op Sinonasal Inflammation. Medtronic Inc., $109,420, 7/2010 to 6/2011.
  • Rodney Schlosser, M.D., PI, Shaun A. Nguyen, M.D., Co-Investigator. Management of Allergic Rhinitis Patients with Nasal Steroids and Low Pressure Nasal Irrigation with Isotonic Saline: A Prospective Pilot Study. NellMed Pharmaceuticals Inc., $67,380, 12/2009 to 6/2011.
  • Rodney Schlosser, M.D., Co-investigator. (PI, Atkinson, C). Nanoparticle coupled therapeutics to inhibit smoke-induced oxidative inflammation in allergic rhinitis. SC Translational Research Institute, $50,000, 2009 to 2010.
  • Rodney Schlosser, M.D., PI. Second-hand smoke exacerbates allergic rhinitis. Flight Attendant Medical Research Institute, Clinical Innovator Award, $325,500, 2008 to 2011.

David R. White, M.D.

  • David R. White, M.D., PI, A prospective, randomized, double-blind placebo-controlled, multicenter, phase 1 study of OTO-201 given as a single intratympanic injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring tympanostomy tube Placement. Otonomy, Inc., $150,591. Sept 1, 2012 to present.
  • David R. White, M.D., PI. Surgical reduction of the inferior turbinate using a coblation device for treatment of nasal obstruction in a pediatric population. Arthrocare, $10,000. Feb 1, 2011 to August 1, 2012
  • Christopher M. Discolo, M.D., PI, David R. White, M.D., Co-Investigator. A Prospective, Multi-Center, Non-Randomized Clinical Trial to Evaluate the Ear Effusion Detection and Characterization System (EEDCS) to Detect and Characterize Middle Ear Fluid in Children. OtoSonics Inc., $23,500, 7/2010 to 6/2011.
  • David R. White, M.D., PI. Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes. Alcon Inc., $76,750, 7/2010 to 6/2012.
  • David R. White, M.D., PI. Natural History Study of Incidence of Otorrhea Following Tympanostomy Tube Insertion in a Cohort of Children Aged 6 Months to 12 Years. Alcon Laboratories, Inc., $35,250 Funding period: May 1, 2010 to March 31, 2012. (1 percent time)
  • David R. White, M.D., PI. Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes. Alcon Laboratories, Inc., $73,750, May 1, 2010 to March 31, 2012.
  • David R. White, M.D., PI. Gastroesophageal reflux in otitis media. National Organization for Hearing Research, $10,000, July 2000 to June, 2001. 
  • David R. White, M.D. As Co-Investigator ;Standardization of video fluoroscopic swallow studies for bottle-fed children. NIH/NIDCD, $396,606, July 2011 to June 2014. PI: Bonnie Martin-Harris, PhD.
  • David R. White, M.D. As Co-Investigator A clinical study of the acclarent tympanostomy tube delivery system in-office. Acclarent, Inc., $3,125, August 2011 to October 2012. PI: Christopher M. Discolo, M.D.
  • David R. White, M.D. As Co-Investigator. Smoke exposure and oxidative inflammation in pediatric chronic rhinosinusitis. American Society of Pediatric Otolaryngology Core Grant., $10,000. July 1, 2010 to June 30, 2011. PI: Jennifer Mulligan, PhD.
  • David R. White, M.D. As Co-Investigator. Ciliary dysfunction in children with otitis media and tobacco exposure. University Research Committee Research Award, Medical University of South Carolina, $2,000, June 1 to October 31, 2010. PI: Steven Andreoli, M.D.
  • David R. White, M.D. As Co-Investigator. Ciliary dysfunction in pediatric atopic disease. American Academy of Otolaryngic Allergy Foundation, $5,000, July 2009 to June 2010. PI: Steven M. Andreoli, M.D.
  • David R. White, M.D. As Co-Investigator. A Prospective, Multi Center, Non-Randomized Clinical Trial To Evaluate The Ear Effusion Detection and Characterization System (EEDCS) to Detect and Characterize Middle Ear Fluid in Children. Sponsored by Otosonics Medical, $25,000, July 2009 to July 2012. PI: Christopher M. Discolo, M.D.
  • David R. White, M.D. As Co-Investigator. Non-randomized feasibility trial to evaluate the ear effusion detection and characterization system (EEDCS) to detect middle ear fluid in children. Sponsored by Otosonics Medical, $15,000, July 2009 to present. PI:Christopher M. Discolo, M.D.

Rita M. Young, Ph.D.

  • Rita M. Young, Ph.D., PI. Defining and Interrupting the Pathways that Lead to HNSCC Invasiveness. VA Medical Center, $125,000, 10/1/07 to 9/30/11.
  • Rita M. Young, Ph.D., PI. Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity. VA Medical Center, $159,000, 10/1/09 to 9/30/14.
  • Rita M. Young, Ph.D., PI. Macrophage-Driven Progression of Premalignant Oral Lesions Toward Invasiveness. NIH/NIDCR, $315,000, 8/1/08 to 6/30/12.
  • Rita M. Young, Ph.D., PI. Immunotherapy to Prevent Oral Permalignant Lesion Recurrence and Oral Cancer. NIH/NCI, $261,450, 1/1/09 to 12/31/13.